Center for Immunotherapy and Cell-Based Technologies

Novosibirsk — Kaliningrad — Moscow — Irkutsk
Main

Astrocytoma

Xenovaccinotherapy for cancer

http://www.medicalnewstoday.com/rss/cancer-oncology.xmlhttp://www.medicalnewstoday.com/rss/immune_system.xmlhttp://www.medicalnewstoday.com/rss/multiple_sclerosis.xmlhttp://www.medicalnewstoday.com/rss/stem_cell_research.xml

  • docid_2.pageCache.php
  • docid_299.pageCache.php
  • docid_304.pageCache.php
  • docid_316.pageCache.php

10.11.2015 Incurable astrocytomas, including the particularly malignant glioblastomas, diffusively grow like mycelium into healthy brain tissue....

04.06.2015 New findings suggest that a gene called IDH1 might be prognostic marker for a rare form of brain cancer. Patients in this study who had a mutated IDH ...

09.04.2014 Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer, according to a new s...

05.02.2014 Astrocytomas are the most common malignant brain tumors. While most patients' tumors prove to be quite aggressive, outcomes overall can vary widely, ...

30.07.2012 Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer from the stressful treatme...

09.07.2011 Novartis Pharmaceuticals Corporation ("Novartis") announced Phase III trial results that showed more than one-third of patients taking Afinitor® (ever...

16.03.2011 Pilocytic astrocytoma, the most common brain tumor in children, is usually slow-growing and benign. However, surgeons often cannot completely remove t...


Immunotherapy for cancer

An active specific immunotherapy (vaccinotherapy) is a strategy using tumor-associated antigens for including antitumor immune responses. The small structural distinctions of the xenogenic tumor-associated antigens from their human analogues render these antigens highly immunogenic and capable of including immune-mediated, antitumor responses in a patient not only at early, but also at advanced stages of disease, when tumor-derived immunosuppression is significant. Tumor-specfic immunotherapy is able to generate a selective and long-term antitumor effect. Such a therapy has no complications attributable to chemotherapy.

Xenovaccinotherapy for cancer